SUNY New Paltz Announces Partnership with eCampus.com as New Official Online Bookstore to Launch in the Summer of 2025
LEXINGTON, Ky., June 18, 2025 /PRNewswire/ -- eCampus.com has been chosen as the official course materials partner for SUNY New Paltz, providing a comprehensive online bookstore platform. Located just 90 minutes from New York City in a vibrant college town, SUNY New Paltz is a competitive, four-year university offering a wide range of undergraduate majors in business, liberal arts and sciences, engineering, fine and performing arts, and education. eCampus.com was selected following a thorough evaluation, which highlighted the company's strong alignment with the university's mission to enrich the experiences of both students and faculty.
SUNY New Paltz is the latest addition to a growing group of SUNY system schools—including Brockport, Canton, Cobleskill, Cortland, Morrisville, Oneonta, Potsdam, Stony Brook, and SUNY Environmental Science & Forestry—that have selected eCampus.com as their comprehensive course materials provider. This partnership aims to deliver convenient and affordable access to course materials through a personalized online storefront. The platform will integrate seamlessly with SUNY New Paltz's Student Information System, streamlining the ordering process through Single Sign-On (SSO) and allowing students to easily order materials.
Key benefits of this new partnership include exceptional customer service, a broader selection of cost-effective options, and the ability to meet the increasing demand for digital content. Students will have access to new, used, and rental textbooks, as well as various digital materials. Additionally, an exclusive Marketplace will allow students to purchase textbooks and course materials from third-party sellers at discounted prices. Students are ensured the most affordable options for textbooks and course materials with eCampus.com's price match guarantee and will receive dedicated customer support via email, chat, or phone. eCampus.com will also offer free shipping to the Gear Shop, where students can conveniently pick up their course materials in store. Our strategic partner University Gear Shop will provide a modern spirit store at SUNY New Paltz. University Gear Shop integrates seamlessly with eCampus Ship2Store Software to ensure efficient package distribution, book buyback, and rental returns in the New Paltz Gear Shop.
The new partnership with eCampus.com offers significant benefits to both SUNY New Paltz students and faculty. Faculty will have access to the FAST adoption platform, which simplifies the research and selection of course materials from over 10 million titles, regardless of publisher or platform. The platform includes pricing comparisons, adoption metrics, and a student readiness dashboard for real-time insights into purchasing behaviors. Faculty can make adoption changes, order desk copies, and access custom materials like lab manuals—all in one place. eCampus.com also provides a dedicated account management team to support faculty with training, guidance, and clear communication, ensuring a smooth transition to the new system. Robust analytics dashboards give leadership visibility into key data, enabling informed decisions at both the institutional and departmental levels.
"We've decided to partner with eCampus and University Gear Shop to provide the campus with the most cutting-edge providers of textbooks and spirit wear available in the marketplace," said Steven Deutsch, Executive Director of Campus Auxiliary Services (CAS), an independent not-for-profit organization that contracts with SUNY New Paltz to provide goods and services to enhance the student experience.
About SUNY New Paltz
Located in the heart of a dynamic college town, 90 minutes from New York City, SUNY New Paltz is a highly selective university of more than 7,000 undergraduate and graduate students.
One of the most well-regarded public universities in the nation, SUNY New Paltz delivers more than 100 programs in Business, Liberal Arts, Sciences, Engineering, Fine & Performing Arts and Education.
New Paltz is a community where talented and independent minded people from around the world create close personal links with real scholars and artists who love to teach.
About Campus Auxiliary Services New Paltz
Campus Auxiliary Services, Inc. (CAS) is an independent not-for-profit organization that contracts with SUNY New Paltz to provide services such as the bookstore. CAS's mission is to provide goods and services to enrich daily life at SUNY New Paltz.
About eCampus.com
eCampus.com is a premier online retailer of textbooks and digital course materials. Consistently exceeding industry standards, eCampus.com's mission is to provide the easiest, fastest, and most affordable way for K-12 and higher education students to buy, rent, or sell textbooks and digital content. Founded on July 2, 1999, eCampus.com reshaped the textbook industry by taking the traditional college bookstore online. Remaining an edtech leader in future-proof course material solutions, eCampus.com serves over 400 schools, colleges, and universities. Their comprehensive course material solutions suite includes full-service online bookstores, inclusive access and equitable access programs, and expert campus store operations and management. Through products that simplify the adoption, management, and procurement of course materials, eCampus.com propels student success by delivering the right course materials, at the right time, and the right price. Learn more at ecampus.com and ecampushighered.com.
Press Contact:
Tiffaney Lavoie859-514-6885http://www.ecampus.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/suny-new-paltz-announces-partnership-with-ecampuscom-as-new-official-online-bookstore-to-launch-in-the-summer-of-2025-302484591.html
SOURCE eCampus.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
30-07-2025
- Fast Company
Snowflake is betting big on agentic AI to transform enterprise data work
While much of the buzz about AI today revolves around flashy copilots and productivity hacks, the reality for most data scientists and data engineering teams remains far less glamorous. Even in 2025, they still spend much of their time on the most tedious part of the job: cleaning and preparing data, i.e., dealing with missing values, duplicates, and inconsistencies. But Snowflake CEO Sridhar Ramaswamy wants to change that—not by replacing the people doing the work, but by eliminating the friction that slows them down, such as the endless cycles of reactive reporting. His bold bet is on agentic AI: autonomous model instances that can ingest data, reason over it, and make real-time decisions with minimal human engineering input. 'Until now, AI tools have been excellent at one-step tasks: You ask a question, you get an answer; you ask for code, you get a snippet. They are powerful assistants, but they require constant direction,' Ramaswamy tells Fast Company. 'In the enterprise [space], agentic AI means goal-directed autonomy.' From Data Silos to Conversational Insight reported its first billion-dollar quarter in May 2025, marking a 26% year-over-year increase.
Associated Press
29-07-2025
- Associated Press
Sabio Announces Launch of Creator Television® on Amazon Fire TV Channels
TORONTO, July 29, 2025 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF) (the 'Company' or 'Sabio'), a Los Angeles-based ad-tech company specializing in helping top global brands reach, engage, and validate (R.E.V.) streaming TV audiences, today announced that its Creator Television ® (Creator TV) free ad-supported television (FAST) channel is now available on Amazon Fire TV Channels. Fire TV Channels, an ad-supported TV experience free to customers on all Fire TV, Fire Tablet, and Echo Show devices in the US, consolidates access to news, sports, music videos, lifestyle, and entertainment channels. Fire TV Channels provides live, on-demand, and short-form content, accessible on the Fire TV home screen and under the 'Free' tab. 'Fire TV Channels has built a distinctive experience that showcases high-quality content across many genres,' said Joe Ochoa, Co-Founder and General Manager of Creator TV. 'We are delighted to bring Creator TV's unique content to the Fire TV audience—and to attract young and diverse audiences to the Fire TV experience.' Creator TV is the first creator-led streaming network and content studio dedicated to bringing the authenticity and energy of social media storytelling to TV. By collaborating with Creator TV, social media content creators can amplify their global presence, diversify their content monetization, and join a TV network, delivering a fresh, dynamic viewing experience. 'Social media creators are the content innovators of our time, and their unique vision and approach will fuel the next wave of programming on TV,' said Charlie Ibarra, Co-Founder and Head of Content at Creator TV. 'Creator-led shows blend the authenticity and deep resonance of user-generated content with traditional TV narrative techniques, expanding the boundaries of storytelling and reshaping how audiences experience entertainment.' Visit to learn more. About Sabio Sabio Holdings (TSXV: SBIO, OTCQB: SABOF) is a technology and services leader in the fast-growing ad-supported streaming space. Its cloud-based, end-to-end technology stack works with top blue-chip, global brands and the agencies that represent them to reach, engage, and validate (R.E.V.) streaming audiences. Sabio consists of a proprietary ad-serving technology platform that partners with the top ad-supported streaming platforms and apps in the world and App Science™, a non-cookie-based software as a service (SAAS) analytics and insights platform with AI natural language capabilities, and Creator Television® (Creator TV), the first creator-led streaming network and content studio dedicated to bringing the authenticity and energy of social media storytelling to TV. For more information, visit: Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information: Sajid Premji, Chief Financial Officer, [email protected], Phone: 1.844.974.2662; Sam Wang, Investor Relations, [email protected] View original content: SOURCE Sabio Inc.
Business Upturn
29-07-2025
- Business Upturn
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
By GlobeNewswire Published on July 29, 2025, 10:15 IST Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infections Study completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the initiation of FORWARD-IM, a phase 3 registrational study evaluating the efficacy and safety of its broad-spectrum antifungal fosmanogepix for the treatment of adult patients with invasive mold infections.[1] Fosmanogepix is a first-in-class antifungal with a novel mechanism of action and is available in both intravenous and oral formulations. It has been evaluated for efficacy and safety in a phase 1 and phase 2 program, including three open-label phase 2 studies for the treatment of Candidemia, including Candida auris , and invasive mold infections.[2, 3, 4, 5, 6] The FORWARD-IM study is the second phase 3 study for fosmanogepix, following the initiation of FAST-IC in September 2024, a randomized, double-blind phase 3 registrational study in adult patients with candidemia and/or invasive candidiasis.[7] Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: 'Our phase 3 program with fosmanogepix allows us to fully explore the clinical benefit of this important new treatment option for invasive fungal infections. Its broad-spectrum activity against multidrug-resistant molds and yeasts highlights the unique potential of fosmanogepix to address significant gaps in current antifungal therapies. Fosmanogepix has shown promising efficacy in earlier clinical studies and in the ongoing expanded access program. The initiation of our second phase 3 study is a significant milestone for fosmanogepix and demonstrates our commitment to advancing our innovative pipeline for the benefit of patients.' FORWARD-IM is an interventional, open-label, two-cohort phase 3 study in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans , Mucorales fungi, or other multidrug-resistant molds. The first cohort will enroll approximately 160 patients, randomized in a 2:1 ratio to receive either fosmanogepix or current standard-of-care therapy. The second cohort will enroll approximately 60 patients who have developed intolerance, toxicities, lack of clinical response, or whose fungal isolate is resistant to standard-of-care therapy. All patients in the second cohort will receive fosmanogepix. The completion of the study and publication of results are expected in 2028. The Swiss-based global company PSI CRO AG is managing the phase 3 program. Basilea acquired fosmanogepix from Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc. Pfizer retains a right of first negotiation for commercializing fosmanogepix, once phase 3 development is successfully completed. This project is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. About fosmanogepix Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus , including multi-drug-resistant strains, such as Candida auris and Candida glabrata , as well as rare difficult-to-treat molds including Fusarium spp., Lomentospora prolificans , Scedosporium spp., and some fungi from the Mucorales order.[2] Fosmanogepix intravenous and oral formulations have been evaluated in phase 2 studies for the treatment of patients with Candidemia, including Candida auris , and invasive mold infections.[4, 5, 6] Fosmanogepix has received Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA) for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP). About invasive mold infections Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Lomentospora prolificans , Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.[8, 9] About invasive candidiasis Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.[10] The prognosis of invasive candidiasis remains unfavorable, with a reported mortality rate as high as 40%, even when patients receive antifungal therapy.[11] About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as 'believe', 'assume', 'expect', 'forecast', 'project', 'may', 'could', 'might', 'will' or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: This press release can be downloaded from References FORWARD-IM (FOsmanogepix study Run Worldwide as Antifungal treatment in Resistant Disease caused by Invasive Molds): identifier: NCT06925321 K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 M. R. Hodges, E. Ople, P. Wedel et al. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 2023 (67), e01623-22 J. A. Vazquez, P. G. Pappas, K. Boffard et al. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial. Antimicrobial Agents and Chemotherapy2023 (67), e01419-22 P. G. Pappas, J. A. Vazquez, I. Oren et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. Journal of Antimicrobial Chemotherapy 2023 (78), 2471-2480 M.R. Hodges, M. Tawadrous, O.A. Cornely et al. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clinical Infectious Diseases 2025 Apr 9:ciaf185 FAST-IC (Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis): identifier: NCT05421858 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: (Accessed: July 28, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456 Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
